Navigation Links
Orchid Cellmark to Announce First Quarter 2009 Financial Results on May 7, 2009
Date:4/27/2009

PRINCETON, N.J., April 27 /PRNewswire-FirstCall/ -- Orchid Cellmark Inc. (Nasdaq: ORCH), a leading worldwide provider of identity DNA testing services, will release its first quarter 2009 financial results on Thursday, May 7, 2009 at approximately 7:00 a.m. EDT, and is hosting a conference call and webcast to discuss the results at 10:00 a.m. EDT on the same day. Management will discuss financial results for the 2009 first quarter as well as operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the live or archived webcast.

          Conference Call Details

             Date and Time:        Thursday, May 7, 2009 at 10:00 a.m. EDT

             Dial-In:              US/Canada:        1-800-860-2442
                                   Int'l/Local:      1-412-858-4600
                                   Conference ID:        430221

             Webcast:  Live webcast and replay available via the Investor
             Relations section of the company's website at
             www.orchidcellmark.com.  The webcast will be available for 90
             days.

About Orchid Cellmark

Orchid Cellmark (Nasdaq: ORCH) is a leading international provider of DNA testing services primarily for forensic and family relationship applications. Orchid Cellmark is one of the largest providers of forensic DNA testing services and its DNA results are used by the criminal justice system to assist with the identification of perpetrators, the exclusion of suspects and the exoneration of wrongfully convicted individuals. The company provides DNA family relationship testing to numerous child services organizations and individuals seeking to verify parentage. Orchid Cellmark also serves immigration and security authorities for DNA testing of individuals. In the agriculture field, the company provides DNA testing services for selective trait breeding. Orchid Cellmark's strong market positions in these areas reflect the company's accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the company's reputation for exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at www.orchidcellmark.com.

All statements in this press release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to the ability to replace the work we previously provided under a subcontractor arrangement, the implementation of government contracts, growing through acquisitions, the potential value of the "mega tender", our potential success in the U.K. National Procurement Plan, expansion of our U.K. facilities, the opportunity for work related to all-arrestee legislation, the potential of property crime testing, operating efficiencies, technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid Cellmark's products and services, dependence on government funding, competition, intellectual property of others, patent protection, litigation, and the timing and amount of contracts put up for bid. These risks and other additional factors affecting these statements and Orchid Cellmark's business are discussed under the headings "Risks Related to Our Business" and "Risks Associated with Our Common Stock" in Orchid Cellmark's Annual Report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Securities and Exchange Commission from time to time. Orchid Cellmark expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid Cellmark's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.


'/>"/>
SOURCE Orchid Cellmark Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Orchid Cellmark Reports Fourth Quarter and Full Year 2008 Financial Results
2. Orchid Cellmark to Announce Fourth Quarter and Year-End 2008 Financial Results on March 16, 2009
3. Orchid Cellmark Reports Third Quarter 2008 Financial Results
4. Orchid Cellmark Reports Second Quarter 2008 Financial Results
5. Orchid Cellmark To Announce Second Quarter 2008 Financial Results on July 31, 2008
6. Orchid Cellmark Reports First Quarter 2008 Financial Results
7. Orchid Cellmark to Open a New Forensic Facility in the United Kingdom to Meet Increasing Demand for Its Services
8. Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results
9. Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
10. Orchid Cellmark Appoints William J. Thomas Vice President and General Counsel
11. Orchid Cellmark Reports Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... a new 21st century approach to infusing high speed technology into the fabric ... exclusively dedicated to the advancement of healthcare and wellness in a yet-to-be-named, health ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... lecture to primary eye care practitioners on the latest breakthroughs in the prevention, ... Semi-Annual Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief ...
(Date:1/17/2017)... , ... January 17, 2017 , ... SC&H Group, a ... as a Principal in its IT Advisory Services practice . Rossi is the ... as market demand for strategic IT guidance grows, and the practice continues to expand.     ...
(Date:1/17/2017)... ... January 17, 2017 , ... Lynx Technology Partners ... US security companies for consecutive years, today announced the appointment of four members ... board nomination process to a close and positions Lynx for even faster growth ...
(Date:1/16/2017)... Creek, MI (PRWEB) , ... January 17, 2017 , ... ... abuse located in Southwest Michigan, joined other volunteers and organizations in support of the ... hundreds of children and families dressed up in colorful costumes of all designs coming ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Jan. 17, 2017   Anesthesia Business Consultants ... practice management for the anesthesia and pain management ... remains a "clinical conundrum" (as described recently in ... practitioners to think carefully before recommending medical marijuana ... by the National Academies of Sciences, Engineering and ...
(Date:1/17/2017)... 17, 2017  In a preview of the upcoming Society ... Astute Medical, Inc., developer of the NephroCheck Test, today highlighted ... identifies hospital patients at risk of developing moderate to severe ... month at the Hawaii Convention Center ... January 25. AKI is one of the top ...
(Date:1/17/2017)... , January 17, 2017 OilPrice.com ... potentially earn millions in revenue with the planned upcoming ... numbers of strokes with a simple test that is ... with latest developments in the markets today include:  Amgen ... AZN ), Cancer Genetics, Inc. (NASDAQ: ...
Breaking Medicine Technology: